ERBB2 and breast carcinoma: Because Par-4 has been reported to play an important role in breast cancer recurrence22–24, we then evaluated the impact of UACA locus on recurrence and progression-free survival (PFS), which includes both recurrence and death, among patients treated with anti-HER2 or doxorubicin chemotherapies.